There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on MariMed (MRMD – Research Report) and Trevi Therapeutics (TRVI – Research Report) with bullish sentiments.
MariMed (MRMD)
Echelon Wealth Partners analyst Andrew Semple reiterated a Buy rating on MariMed today and set a price target of $0.40. The company’s shares closed last Thursday at $0.28.
According to TipRanks.com, Semple is a 1-star analyst with an average return of
Currently, the analyst consensus on MariMed is a Moderate Buy with an average price target of $0.40.
See Insiders’ Hot Stocks on TipRanks >>
Trevi Therapeutics (TRVI)
B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Trevi Therapeutics today and set a price target of $6.00. The company’s shares closed last Thursday at $2.99.
According to TipRanks.com, Mamtani has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Trevi Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $7.40, a 179.2% upside from current levels. In a report released yesterday, Needham also maintained a Buy rating on the stock with a $8.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MRMD:
- Statement From MariMed CEO And President Jon Levine Regarding The Drug Enforcement Administration’s Decision To Recategorize Cannabis To Schedule III
- MariMed Closes Acquisition of Thrive Dispensary in Casey, The Company’s Fifth Illinois Dispensary
- Marimed closes acquisition of Thrive Dispensary in Casey, Illinois
- Marimed partners with Boston music venues
- MariMed Partners with Iconic Boston Music Venues
